Vir Biotechnology Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Vir Biotechnology Inc 's ROA in the second quarter of 2026?
Vir Biotechnology Inc recorded a cumulative net loss of $-252 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -23.64%.

However, within the Healthcare sector 381 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3812, from total ROA ranking in the first quarter of 2026 at 4432.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	32.55 %	-6.41 %	-25.2 %	-13.28 %	-31.68 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-252	-443	-438	-500	-550
Return On Assets (TTM)	-23.64 %	-44.7 %	-43.46 %	-45.74 %	-48.63 %
VIR's Total Ranking	# 3812	# 4432	# 3912	# 3956	# 4013
Total Assets (TTM) in million	1,211	1,026	1,003	1,019	913
Seq. Total Assets Change	18.05 %	2.27 %	-1.63 %	11.61 %	-16.65 %
Seq. Net Income Change	-	-	-	-	-

VIR's 5 Years Annual ROA >> Back to VIR Management Effectiveness >> Compare VIR ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 38
Sector	# 382
Overall	# 3492

Return On Assets Statistics
High	Average	Low
68.43 %	-16.99 %	-55.69 %
(Mar 31 2022)		(Mar 31 2020)

News about Vir Biotechnology Inc Return on Assets ROA

Navigating the Landscape of Innovation and Financial Performance in Biopharma A Case Study of Vir Biotechnologys Col...

: Vir Biotechnology, Inc. has recently entered into an exclusive worldwide license agreement with Sanofi concerning the development of clinical-stage T-cell engagers (TCEs), a promising class of immunotherapeutic agents with potential applications across various cancer types. This collaboration marks an important milestone for Vir Biotechnology, as it aligns strategic partnerships with the need for growth in a highly competitive biopharmaceutical landscape. However, financial metrics reveal challenges, including significant net losses and a concerning return on assets. This article examines the implications of the collaboration and the broader financial context in which Vir operates, highlighting both its innovative potential and financial hurdles.The biopharmaceutical industry is characterized by rapid innovation and strategic alliances aimed at enhancing product pipelines and accelerating clinical development. Vir Biotechnology s recent licensing agreement with Sanofi underscores this trend, granting Vir exclusive rights to develop three clinical-stage masked T-cell engagers. These agents are designed to enhance the immune system s ability to target and destroy cancer cells, reflecting a growing focus on immunotherapies in oncology. However, financial metrics portray a sobering picture for the company, which has reported substantial cumulative losses and negative asset returns.

Financial Statements
Vir Biotechnology Inc 's Assets	$ 1,211 million	VIR's Balance sheet
Vir Biotechnology Inc 's Income	$ 80 million	Quarterly VIR's Income Statement
VIR's Income by Division		See VIR's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-1.74 %	-27.53 %	-32.07 %	45.61 %	117.22 %
Total Assets in million	1,317	1,341	1,850	2,723	1,870
Y / Y Net Income Change	-	-	-	-2.41 %	-
Net Income in million	-438	-522	-615	516	529
Annual Return On Assets	-33.25 %	-38.93 %	-33.25 %	18.94 %	28.26 %

VIR's 5 Years Annual ROA >> Back to VIR Management Effectiveness >> Compare VIR ROA to its Competitors

More Return On Assets Ratios
VIR's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
VIR's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for VIR's Competitors
Subscribers only: Roa for Vir Biotechnology Inc 's Suppliers
Subscribers only: Return On Assets for VIR's Customers

You may also want to know
VIR's Roi	VIR's Inventory Turnover Ratio	VIR's Growth Rates	VIR's Dividend Comparisons
	VIR's Profitability Ratios	VIR's Asset Turnover Ratio	VIR's Dividend Growth
VIR's Roe	VIR's Valuation Ratios	VIR's Financial Strength Ratios	VIR's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T22:46:44+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.